Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.

Twenty-three patients with advanced colorectal carcinoma, previously treated with chemotherapy, were entered in a phase II trial of DON (6-Diazo-5-Oxo-l-Norleucine), an antagonist of l-glutamine. One of 14 adequately treated patients had a partial response of 6 weeks duration. The dose-limiting toxi